Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 4/20 | 0.52 |
| ▸ | MMP3 | P08254 | 4/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
| ▸ | FURIN | P09958 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | CPA2 | P48052 | 1/20 | 0.46 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22695740 | 1.00 | GNPAT (0.54) | GNPATMMP1MMP3OPRK1MMP9 | |
| SCHEMBL15499735 | 0.96 | GNPAT (0.55) | GNPATMMP1MMP3OPRK1MMP9 | |
| SCHEMBL22845647 | 0.93 | GHSR (0.55) | GNPATGHSRFURINERAP2LNPEP | |
| SCHEMBL18499711 | 0.93 | GHSR (0.55) | GNPATGHSRFURINERAP2LNPEP | |
| SCHEMBL30917923 | 0.91 | GNPAT (0.61) | GNPATMMP2CPB2ERAP2LNPEP | |
| SCHEMBL14821599 | 0.90 | MMP1 (0.57) | GNPATMMP1MMP3MMP9MMP2 | |
| SCHEMBL22600860 | 0.89 | GNPAT (0.53) | GNPATMMP1MMP3OPRK1MMP9 | |
| SCHEMBL14553984 | 0.89 | GNPAT (0.48) | GNPATMMP1MMP3OPRK1MMP9 | |
| SCHEMBL23128421 | 0.88 | GNPAT (0.52) | GNPATMMP1MMP3OPRK1MMP9 | |
| SCHEMBL21503809 | 0.88 | GNPAT (0.52) | GNPATMMP1MMP3OPRK1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121632-A1 | USE OF ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC) | CRISPR THERAPEUTICS AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024064771-A1 | ANTI-CD45-IGN ANTIBODY DRUG CONJUGATES AND USES THEREOF | VOR BIOPHARMA INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2023002415-A2 | METHODS AND COMPOSITIONS FOR ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC) TREATMENT | Magenta Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3960767-A2 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | Novartis AG (CH) | 2022-03-02 | — | — | EP | disclosed |
| WO-2020219774-A1 | ANTHRACYCLINE ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020146432-A1 | USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160067351-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| WO-2015138615-A2 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | IRM LLC (BS) | 2015-09-17 | — | — | WO | disclosed |
| WO-2014124316-A2 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | IRM LLC (BM) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | GNPAT 2288/4885MMP1 4850/4885MMP3 3691/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | GNPAT 520/4885MMP1 2260/4885MMP3 1325/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | GNPAT 3147/4885MMP1 1985/4885MMP3 2516/4885 |
| US-20160067351-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | PTMS, FCGR2A, FCGR3B | GNPAT 2249/4885MMP1 2925/4885MMP3 4034/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | GNPAT 2024/4885MMP1 2602/4885MMP3 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.